Belzutifan Practical Guidance in Advanced Clear-Cell RCC

Authored by Toni Choueiri, published on 2026-09-16 22:02:01.0

This belzutifan-focused pathway is broadly aligned with current evidence and labeling for advanced/metastatic ccRCC after prior PD-(L)1 inhibitor and VEGF-targeted therapy, centering on LITESPARK-005 and the WELIREG prescribing information. The algorithm appropriately emphasizes baseline and on-treatment monitoring for mechanism-related anemia and hypoxia and includes pragmatic dose interruption/reduction concepts. Its scope is appropriately narrow (monotherapy, later-line) and correctly defers broader sequencing to other pathways.

Confirm advanced clear-cell RCC treatment context

This pathway applies to adults with advanced or metastatic renal cell carcinoma with a clear-cell component who are being considered for belzutifan monotherapy. Confirm: Clear-cell RCC or RCC with a clear-cell component Advanced, unresectable, or metastatic disease Prior systemic therapy history Prior PD-1 or PD-L1 inhibitor exposure Prior VEGF-TKI exposure Current disease burden and sites of metastases Disease tempo and symptoms ECOG performance status Prior immune-related adverse events Prior VEGF-TKI toxicity Comorbidities, pulmonary status, anemia risk, patient goals, access, and logistics This is an advanced/metastatic ccRCC belzutifan monotherapy pathway. This is not: an adjuvant pembrolizumab + belzutifan pathway; a VHL-associated RCC pathway; a PPGL pathway; a non-clear-cell RCC pathway; a broad RCC sequencing pathway.
- Prior PD-(L)1 inhibitor and VEGF-TKI exposure?
  
  Belzutifan monotherapy is most directly supported in advanced clear-cell RCC after prior PD-1 or PD-L1 inhibitor and VEGF-TKI exposure. Confirm whether the patient has received: PD-1 or PD-L1 checkpoint inhibitor VEGF-TKI Both therapies either sequentially or in combination Number of prior systemic therapy lines Prior mTOR inhibitor, HIF-2α inhibitor, or investigational therapy if any Reason for prior treatment discontinuation: progression, toxicity, patient preference, access, or other reason If the patient has not received prior PD-(L)1 inhibitor and VEGF-TKI exposure, use an appropriate first-line or earlier-line RCC pathway, clinical trial, or expert-guided alternative strategy.
  - Use appropriate RCC pathway / clinical trial
    
    If the patient does not fit the advanced ccRCC post–PD-(L)1 and VEGF-TKI treatment context, use the appropriate RCC pathway. First-line advanced ccRCC treatment-selection pathwayConsider: Subsequent-line RCC sequencing pathway Adjuvant RCC pathway if post-nephrectomy without metastatic progression VHL-associated RCC pathway if applicable Non-clear-cell RCC pathway if non-clear-cell histology predominates PPGL pathway if relevant Clinical trial when available This is a terminal hand-off node, not a loop.
  - Confirm this is the advanced ccRCC belzutifan monotherapy scenario
    
    Before proceeding, confirm that the patient belongs in this advanced ccRCC belzutifan monotherapy pathway. This pathway is for: Advanced or metastatic clear-cell RCC or RCC with a clear-cell component Prior PD-(L)1 inhibitor exposure Prior VEGF-TKI exposure Consideration of belzutifan monotherapy Separate pathways should be used for: Adjuvant pembrolizumab + belzutifan after nephrectomy VHL-associated RCC or other VHL-associated tumors Locally advanced, unresectable, or metastatic PPGL Non-clear-cell RCC without a clear-cell component First-line advanced RCC treatment selection Broad RCC sequencing decisions outside the belzutifan-specific use case This algorithm is designed as a focused practical guidance pathway for belzutifan monotherapy in advanced ccRCC after prior PD-(L)1 inhibitor and VEGF-TKI.
    - Assess suitability for belzutifan
      
      Assess whether belzutifan is appropriate for the patient’s clinical status, treatment goals, and ability to complete safety monitoring. Clinical risk: Review anemia and transfusion history, respiratory symptoms and oxygen requirement, cardiopulmonary comorbidities, renal and hepatic function, performance status, frailty, fatigue, and prior treatment tolerance. Feasibility and preferences: Review concomitant medications, reproductive considerations, oral treatment adherence, access, and the patient’s priorities regarding treatment burden and adverse effects. Significant baseline anemia, impaired oxygenation, or substantial pulmonary disease warrants an individualized benefit–risk discussion and evaluation of reversible contributors before proceeding. Arrange closer monitoring when treatment remains appropriate.
      - Baseline hemoglobin and oxygen saturation assessment
        
        Complete and review the baseline laboratory and clinical assessments before starting belzutifan. Clinical evaluation: Document resting oxygen saturation, dyspnea, other respiratory symptoms, and any supplemental oxygen requirement. Review relevant cardiopulmonary disease and concomitant medications. Assess exertional oxygen saturation and obtain pulmonary evaluation when clinically indicated. Note: Assess iron status even when hemoglobin is near-normal or normal; iron deficiency may coexist and complicate the interpretation and management of treatment-related anemia. Clinically significant anemia or impaired oxygenation requires evaluation and an individualized treatment plan before initiation. A single hemoglobin or oxygen saturation value does not establish overall treatment suitability.
        
        Is belzutifan appropriate, safe, and available?
        
        Proceed with belzutifan if: Advanced/metastatic ccRCC treatment context is confirmed Prior PD-(L)1 inhibitor and VEGF-TKI exposure is documented No better pathway applies Baseline hemoglobin is acceptable or manageable Baseline oxygen saturation is acceptable or manageable Pulmonary risk is acceptable or manageable Patient can comply with monitoring Access and regulatory/payer requirements support treatment Patient understands anemia, hypoxia, fatigue, dyspnea, and monitoring requirements If belzutifan is not appropriate, safe, or available, use an alternative standard RCC next-line pathway, clinical trial, best supportive care when appropriate, or expert multidisciplinary review.
        
        Alternative standard next-line RCC pathway / clinical trial
        
        Use an alternative RCC next-line strategy when belzutifan is not clinically appropriate, not available, not preferred, or not supported by local access/regulatory criteria. Consider: VEGFR-TKI sequencing Tivozanib, cabozantinib, lenvatinib/everolimus, axitinib, or other locally available options according to prior exposure and guideline context Clinical trial Best supportive care when appropriate Local therapy for oligoprogression when clinically relevant Symptom burden, disease tempo, prior toxicities, comorbidities, access, and patient goals This is a terminal hand-off node, not a loop.
        
        Start belzutifan
        
        Initiate belzutifan monotherapy after reviewing baseline safety assessments and medication interactions. Confirm the monitoring plan and ensure the patient knows how to contact the care team for new or worsening dyspnea, dizziness, fatigue, chest symptoms, or oxygen desaturation. Complete counseling on administration, reproductive risks, contraception, breastfeeding, and adherence before the first dose.
        
        Monitoring during therapy
        
        Monitor hemoglobin, oxygenation, symptoms, and functional status throughout treatment. Consider closer assessment during the first 1–2 months, after a clinically significant change, and after treatment interruption or restart. Monitoring frequency should reflect baseline risk, laboratory trends, symptoms, and local practice. New or worsening dyspnea, dizziness, fatigue, chest symptoms, or oxygen desaturation should prompt assessment rather than waiting for the next scheduled visit. Use the anemia and hypoxia management pathways when relevant. Patients may require evaluation for both toxicities at the same time.
        
        Anemia management
        
        Assess the severity, symptoms, and trajectory of anemia. Evaluate clinically relevant contributors, including bleeding, iron or vitamin deficiency, renal dysfunction, inflammation, marrow involvement, and disease progression. Hemoglobin <8 g/dL or transfusion indicated: Withhold belzutifan until hemoglobin is ≥8 g/dL. After reassessment, resume at the same or a reduced dose, or discontinue, according to severity. Life-threatening anemia or urgent intervention indicated: Withhold belzutifan and provide urgent supportive care. Once the event has resolved and hemoglobin is ≥8 g/dL, resume at a reduced dose or permanently discontinue. Correct reversible contributors and transfuse when clinically indicated. Reassess symptoms, functional status, and oxygenation before restarting treatment. Iron assessment and replacement: expert practice Intravenous iron may be used to correct iron deficiency when appropriate. Intensive serial iron testing is not required in clinically stable patients; annual reassessment may be sufficient unless clinical findings warrant earlier testing. Reassess sooner when hemoglobin declines, anemia symptoms develop, or another cause is suspected. This approach applies to iron studies, not to hemoglobin or oxygen saturation monitoring.
        
        Hypoxia management
        
        Assess new or worsening hypoxia promptly. Provide supplemental oxygen and urgent or emergency care when clinically indicated, while evaluating alternative or contributing causes. Exercise-associated desaturation, such as SpO₂ <88%: Consider withholding belzutifan. Resume only after resolution, with exertional SpO₂ >88%, at the same or a reduced dose according to severity. Resting hypoxia, such as SpO₂ <88% or PaO₂ ≤55 mm Hg, or urgent intervention indicated: Withhold belzutifan until resolution. Resume at a reduced dose or discontinue according to severity. Life-threatening hypoxia or recurrent symptomatic hypoxia: Permanently discontinue belzutifan. Evaluate relevant causes, including pulmonary embolism, infection, pleural disease, pulmonary progression, underlying lung or cardiac disease, and treatment-related pneumonitis. Assess coexisting anemia and other contributors to symptoms.
        
        Response assessment
        
        Assess response using standard RCC clinical and radiographic follow-up. Consider: Symptoms and performance status Disease-related pain Weight, appetite, and functional trajectory Imaging by RECIST-oriented practice when appropriate Sites at risk: lung, bone, lymph nodes, liver, brain if clinically indicated Treatment tolerance and cumulative toxicity Patient goals and quality of life Belzutifan may have a different toxicity profile than VEGF-TKIs or immune checkpoint inhibitors. Treatment continuation should be based on disease control, tolerability, patient goals, and absence of unacceptable toxicity. If there is mixed response or oligoprogression, consider multidisciplinary review and local therapy where appropriate, but avoid looping within this algorithm.
        
        Progression or unacceptable toxicity: next-line hand-off
        
        At radiographic progression, clinical progression, or unacceptable toxicity, reassess the full RCC context. Confirm: Prior PD-(L)1 exposure Prior VEGF-TKI exposure Prior mTOR inhibitor exposure Prior belzutifan exposure and reason for discontinuation Disease tempo Symptom burden Sites of progression Performance status Organ function Eligibility for clinical trial Suitability for VEGFR-TKI, mTOR-based therapy, other systemic options, local therapy, or best supportive care Terminal hand-off: Open post-belzutifan RCC sequencing pathway, clinical trial pathway, local therapy review, or best supportive care pathway when appropriate. Key caveats: This algorithm is focused on belzutifan monotherapy for advanced clear-cell RCC after prior PD-(L)1 inhibitor and VEGF-TKI exposure. Do not mix this pathway with adjuvant pembrolizumab + belzutifan, VHL-associated RCC, PPGL, or non-clear-cell RCC; these require separate algorithms. The central implementation issue is not only whether belzutifan is indicated, but whether the patient can be safely monitored and managed for anemia and hypoxia. Baseline hemoglobin and oxygen saturation should be documented before starting therapy. Patients with baseline anemia, pulmonary comorbidity, lung metastases, oxygen requirement, or borderline oxygen saturation require individualized risk-benefit discussion and closer monitoring. Dose interruption and reduction are key safety tools. Dose reduction sequence is 120 mg → 80 mg → 40 mg → discontinue. Expert faculty review is recommended, particularly for borderline oxygenation, severe baseline anemia, unusual sequencing, adjuvant/post-adjuvant relapse, or non-clear-cell histology. This is a terminal node. Do not loop back to earlier belzutifan selection steps.

tos privacy Choueiri TK, Powles T, Peltola K, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024;391:710-721.Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021;27:802-805. PMID: 33888901.WELIREG (belzutifan) Prescribing Information. Merck. Revised June 2026.LITESPARK-005 / NCT04195750: Belzutifan versus Everolimus in Advanced Clear-Cell RCC.FDA approves belzutifan for advanced renal cell carcinoma.Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021;385:2036-2046. PMID: 34818478.